07 Oct 2026, 08:43 IST
Divi's Laboratories Limited
Motilal Oswal Financial Services Ltd. (MOFSL) · BUY · target Rs 10,800
The note's velocity idea says Divi's is positioned to benefit from oral Wegovy-driven peptide API demand and 0% US tariff clarity, expecting 21% earnings CAGR over FY26-28, with CMP Rs 9,540, SL Rs 8,870; it also lists a DIVISLAB 9600 CE buy on long build-up.
From MOStMarketOutlook07102026, written by Motilal Oswal Financial Services Ltd. (MOFSL) and hosted by Investment Guru India. Orivam summarised it; the view is Motilal Oswal Financial Services Ltd. (MOFSL)'s, not Orivam's.
Open the original PDF on Investment Guru India →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.